Diagnostic markers for community-acquired pneumonia.

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Biomarker Research

Background:

• Community-acquired pneumonia (CAP) presents diagnostic challenges due to diverse causes (bacterial, viral, non-infectious).
• Traditional inflammatory biomarkers (WBC, CRP, ESR) lack specificity for bacterial CAP, often elevated in other conditions.
• Accurate differentiation is crucial for appropriate antibiotic use and patient management.

Purpose of the Study:

• To review and discuss the characteristics of emerging inflammatory biomarkers for diagnosing CAP.
• To evaluate the utility of newer biomarkers in differentiating bacterial CAP from viral CAP and non-infectious respiratory diseases.
• To highlight the potential of biomarkers like procalcitonin (PCT) in CAP diagnosis.

Main Methods:

• Literature review of studies evaluating inflammatory biomarkers in CAP.
• Analysis of biomarker characteristics, including specificity and sensitivity for bacterial infection.
• Comparison of novel biomarkers (PCT, sTREM-1, proADM, presepsin) with traditional markers.

Main Results:

• Novel biomarkers such as procalcitonin (PCT), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), pro-adrenomedullin (proADM), and presepsin demonstrate higher specificity for bacterial infections.
• Procalcitonin (PCT) has been extensively studied for its role in CAP diagnosis and differentiating bacterial from viral etiologies.
• Traditional biomarkers show limitations in specificity, being elevated in non-infectious inflammatory conditions.

Conclusions:

• Emerging biomarkers offer improved accuracy in diagnosing bacterial CAP compared to traditional markers.
• Procalcitonin (PCT) is a key biomarker for guiding antibiotic therapy decisions in CAP.
• Further research into biomarker panels may enhance diagnostic precision for respiratory diseases.